How Much Does Saxenda Cost in Missouri in 2026?

Saxenda Retail Pricing Across Missouri

The manufacturer list price set by Novo Nordisk for Saxenda is $1,349 per month for a supply of five 3 mL prefilled pens (18 mg total per pen). This price holds relatively steady across Missouri retail pharmacies, from Kansas City to St. Louis to Springfield.

Retail pricing at Missouri chain pharmacies tends to cluster near the list price. Independent pharmacies may offer modest discounts, but dramatic variation is uncommon for brand-name GLP-1 receptor agonists. The 2026 pricing environment for Saxenda in Missouri reflects a broader national pattern: with semaglutide products (Wegovy, Ozempic) absorbing most of the market's attention and supply-chain investment, Saxenda pricing has not seen the competitive pressure that might otherwise drive reductions.

Patients paying cash should compare prices at multiple Missouri pharmacies. Pharmacy benefit managers negotiate different rates, and a price at a Walgreens in Columbia may differ from one at a Costco in Independence by $50 to $150. Using a pharmacy discount aggregator can sometimes yield savings of 5% to 12% off list, though this depends on the specific pharmacy's contract.

One clinical point worth noting: Saxenda requires dose titration over four to five weeks. The first month's supply typically lasts longer than 30 days because patients begin at 0.6 mg daily and increase by 0.6 mg each week until reaching the maintenance dose of 3 mg [1]. This means the effective first-month cost is lower than $1,349, since fewer pens are consumed during titration.

Missouri Medicaid and Saxenda Coverage

Missouri Medicaid does not cover Saxenda for chronic weight management. Coverage for liraglutide under Missouri's Medicaid program is restricted to the 1.8 mg dose (marketed as Victoza) for type 2 diabetes treatment only.

This exclusion aligns with how most state Medicaid programs handle anti-obesity medications. Despite the American Association of Clinical Endocrinology's 2023 guidelines recognizing obesity as a chronic disease warranting pharmacotherapy, many Medicaid formularies still classify weight-management drugs as "lifestyle" medications and exclude them. Missouri has not updated its formulary to include Saxenda or other GLP-1 receptor agonists for obesity as of mid-2026.

For Missouri Medicaid beneficiaries who also carry a type 2 diabetes diagnosis, the situation is different. Liraglutide at the 1.8 mg dose (Victoza) may be covered under the diabetes treatment benefit, subject to prior authorization. However, the 3 mg Saxenda formulation specifically indicated for weight management remains excluded.

Missouri expanded Medicaid eligibility under Amendment 2 in 2020, broadening coverage to adults earning up to 138% of the federal poverty level. This expansion brought approximately 275,000 new enrollees into the program. None of these enrollees have Saxenda coverage for weight management under current formulary rules.

Patients on Missouri Medicaid who want access to GLP-1-based weight management should discuss alternatives with their prescriber. Some may qualify for manufacturer patient assistance programs, and others may find compounded liraglutide to be a viable route.

Commercial Insurance Coverage in Missouri

Commercial insurance coverage for Saxenda in Missouri varies significantly by carrier and plan tier. Some plans cover it with prior authorization, others exclude it entirely, and a few newer plans cover it with a specialty-tier copay.

The most common requirements for Saxenda coverage on Missouri commercial plans include: a documented BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity), evidence of a structured diet and exercise program lasting three to six months, and prior authorization from the prescribing provider [2]. Plans offered through employers in Missouri's larger metro areas, particularly St. Louis and Kansas City, tend to have somewhat broader formulary inclusion than individual marketplace plans.

Blue Cross Blue Shield of Kansas City, one of Missouri's larger commercial insurers, requires prior authorization for Saxenda and classifies it as a non-preferred brand. UnitedHealthcare plans in Missouri similarly require prior authorization, with step therapy through lifestyle modification as a prerequisite. Cigna plans sold in Missouri have historically excluded anti-obesity medications from standard formularies, though some employer-sponsored Cigna plans include them.

Patients should call the number on the back of their insurance card and ask specifically: "Is liraglutide 3 mg (Saxenda) covered under my pharmacy benefit for weight management, and what is my cost share?" The answer often differs from what online formulary tools display, because employer-level carve-outs can override the insurer's standard formulary.

Dr. Caroline Apovian, a leading obesity medicine researcher, has stated: "The gap between clinical guidelines recommending anti-obesity medications and insurance coverage of those medications remains one of the biggest barriers to evidence-based obesity treatment in the United States" [3].

The Novo Nordisk Savings Card in Missouri

Novo Nordisk offers a manufacturer savings card that can reduce Saxenda's out-of-pocket cost for commercially insured patients. Eligible patients may pay as little as $25 per month for up to 12 months.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Saxenda, even partially. Patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs are not eligible. Missouri residents with qualifying commercial insurance can enroll online or through their prescriber's office.

The savings card works by covering the difference between the patient's copay or coinsurance and $25, up to a maximum annual benefit. For a patient whose insurance leaves a $200 monthly copay, the card covers $175 per fill. The annual cap has varied by program year; patients should verify the current maximum at enrollment.

One limitation: the savings card does not help uninsured patients or those whose plans explicitly exclude Saxenda. For patients in those categories, other cost-reduction strategies become necessary.

Compounded Liraglutide 3 mg in Missouri

Compounded liraglutide 3 mg is available in Missouri through licensed 503A compounding pharmacies. This option has become increasingly relevant for patients priced out of brand-name Saxenda.

Under federal law, 503A pharmacies compound medications based on individual patient prescriptions. In Missouri, the State Board of Pharmacy regulates these pharmacies under Chapter 338 of the Missouri Revised Statutes. A Missouri-licensed prescriber must write an individual prescription for compounded liraglutide, and the compounding pharmacy must use ingredients sourced from FDA-registered suppliers.

Pricing for compounded liraglutide in Missouri varies by pharmacy. Some 503A pharmacies offer monthly supplies at substantially lower cost than brand Saxenda. Patients should verify that any compounding pharmacy they use holds a current Missouri Board of Pharmacy license and sources its liraglutide base from an FDA-registered facility.

A few important clinical considerations apply. Compounded liraglutide is not FDA-approved. It does not carry the same labeling, lot-by-lot release testing, or post-market surveillance as Novo Nordisk's manufactured product. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity notes that compounded peptides should be discussed with patients in terms of both cost advantages and quality-control differences relative to FDA-approved products.

Patients considering compounded liraglutide should ask their pharmacy: What is the source of the active pharmaceutical ingredient? What potency and sterility testing do you perform? What is your beyond-use date assignment? These questions help distinguish rigorous compounders from less reliable ones.

Telehealth Access to Saxenda in Missouri

Missouri permits telehealth prescribing of Saxenda. Patients can obtain a prescription through a licensed telehealth provider without an in-person visit.

Missouri's telehealth regulations, updated through the Missouri Telemedicine Act, allow prescribers to establish a patient-provider relationship via synchronous audio-video consultation. This means a Missouri resident in rural areas, where obesity medicine specialists are scarce, can access the same prescribing as someone in downtown St. Louis.

Several national telehealth platforms serve Missouri patients seeking Saxenda prescriptions. These platforms typically charge a consultation fee ($50 to $199 for an initial visit), and the prescription is sent to the patient's pharmacy of choice. Some telehealth platforms also partner with compounding pharmacies, bundling the consultation and medication into a single monthly fee.

HealthRX offers telehealth consultations for Missouri patients interested in GLP-1 receptor agonist therapy, including liraglutide 3 mg. Board-certified providers evaluate each patient's medical history, BMI, comorbidities, and medication interactions before prescribing.

Clinical Efficacy: What You Get for the Cost

Understanding what Saxenda delivers clinically helps contextualize its price. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss at 56 weeks, compared with 2.6% for placebo [1]. Sixty-three percent of patients on liraglutide lost at least 5% of their body weight, versus 27% on placebo.

Beyond weight loss, the SCALE trial showed metabolic benefits. Liraglutide 3 mg reduced the prevalence of prediabetes by 52% relative to placebo over three years of follow-up. Systolic blood pressure decreased by 2.8 mmHg more than placebo. HbA1c dropped by 0.23 percentage points more than placebo in participants without diabetes [1].

These results compare to newer GLP-1 receptor agonists. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) [4], and tirzepatide (Mounjaro/Zepbound) achieved up to 22.5% in the SURMOUNT-1 trial (N=2,539) [5]. Saxenda's weight-loss magnitude is more modest, but it has a longer track record (FDA-approved in 2014) and more extensive post-market safety data.

The FDA's prescribing information for Saxenda recommends discontinuing treatment if a patient has not achieved at least 4% weight loss by 16 weeks at the full 3 mg dose [2]. This built-in stopping rule prevents patients from spending months on an ineffective therapy.

Cost-Reduction Strategies for Missouri Patients

Several approaches can lower Saxenda costs for Missouri patients beyond the savings card and compounding options already discussed.

Pharmacy shopping. Prices at Missouri pharmacies are not uniform. Checking three to five pharmacies, including at least one warehouse club (Costco, Sam's Club) and one independent, can reveal price differences of $50 to $200 per month. Warehouse club pharmacies do not require membership for prescription fills in Missouri.

Manufacturer patient assistance. Novo Nordisk operates a patient assistance program for uninsured patients meeting income requirements (generally at or below 400% of the federal poverty level). Eligible patients may receive Saxenda at no cost. Application requires documentation of income and insurance status.

Prior authorization appeals. If a commercial insurer denies Saxenda coverage, Missouri patients have the right to appeal. A peer-to-peer review, where the prescribing physician speaks directly with the insurance company's medical director, succeeds in overturning denials in a meaningful percentage of cases. The prescriber should cite the patient's BMI, comorbidities, and failed lifestyle interventions.

Flexible spending and health savings accounts. Saxenda is an eligible expense under FSA and HSA plans. Missouri patients enrolled in high-deductible health plans with HSAs can pay for Saxenda with pre-tax dollars, effectively reducing the cost by their marginal tax rate.

The American Medical Association's 2023 policy statement on anti-obesity medication access noted: "Arbitrary exclusion of FDA-approved anti-obesity medications from insurance formularies is inconsistent with the recognition of obesity as a chronic disease and impedes evidence-based treatment" [6].

Side Effects and Monitoring Costs

The out-of-pocket cost of Saxenda extends beyond the medication itself. Patients should budget for associated monitoring and potential side-effect management.

Common side effects of liraglutide 3 mg include nausea (39% of patients in SCALE), diarrhea (21%), constipation (19%), and injection-site reactions (14%) [1]. Nausea is most pronounced during the dose-titration phase and typically diminishes after four to six weeks. The slow titration schedule (starting at 0.6 mg and increasing weekly by 0.6 mg to the 3 mg maintenance dose) is specifically designed to reduce gastrointestinal side effects.

Monitoring requirements are minimal. Baseline labs (fasting glucose, HbA1c, lipid panel, liver function tests) cost $50 to $200 depending on insurance coverage. Follow-up labs at 12 to 16 weeks add another cycle. Patients with a personal or family history of medullary thyroid carcinoma should not use Saxenda; this contraindication is boxed in the FDA label [2].

For patients on concurrent diabetes medications, hypoglycemia risk increases. Dose adjustments to sulfonylureas or insulin may be necessary, requiring closer monitoring during Saxenda initiation. This adds follow-up visit costs but does not typically require expensive testing.

Patients starting Saxenda through HealthRX receive ongoing provider support, including check-ins during the titration period and lab-order coordination, at no additional visit charge beyond the initial consultation fee.